.
.
.
.

Longer dosing interval makes its coronavirus vaccine more effective, says Sinovac

Published: Updated:

China’s Sinovac Biotech said on Monday that a clinical trial in Brazil showed its COVID-19 vaccine was almost 20 percentage points more effective in a small sub-group of patients who received their two doses longer apart.

For more coronavirus news, visit our dedicated page.

The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70 percent, a Sinovac spokesman said.

For all the latest headlines follow our Google News channel online or via the app

Brazilian researchers announced last week that the vaccine’s overall efficacy was 50.4 percent based on results from more than 9,000 volunteers, most of whom received doses 14 days apart, as outlined in the trial protocol.

The spokesman said a small number of participants received their second shot late due to a various reasons, without elaborating.

The dosing interval for COVID-19 vaccines has become a hot topic of debate among scientists, regulators and governments.

UK regulators have said a COVID-19 vaccine from AstraZeneca and Oxford University is more effective when there is a longer gap between doses than initially envisaged.

Read more:

Coronavirus: Brazil begins COVID-19 vaccination campaign

Coronavirus: China locks down 3 mln people amid COVID-19 outbreak linked to salesman

Coronavirus: Israel exchanges medical data for Pfizer COVID-19 vaccine doses


Britain has also decided to allow a longer gap between doses of a COVID-19 vaccine from Pfizer and BioNTech, even though the companies say they only have efficacy data for a shorter period between shots.

The Sinovac spokesman cautioned the robustness of the data from the sub-group was weaker than the 50 percent result, which is based on the combined data of those receiving doses two or three weeks apart.

While Sinovac’s researchers had said early stage trials showed a four-week interval induced the stronger antibody response than two weeks, this is the first time the company has released efficacy data from a Phase III trial with dosing patterns that differ from its trial protocol.

Sinovac has yet to release global results of its Phase III trials, but its COVID-19 vaccine has been approved for emergency use in several countries, including Brazil, Indonesia and Turkey.